Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity
- PMID: 8086134
- DOI: 10.1097/00002030-199406000-00007
Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity
Abstract
Objective: To determine the relationships between in vivo zidovudine (ZDV) phosphorylation in cells from HIV-infected patients and markers associated with disease progression and drug toxicity.
Design: A pharmacokinetic study of ZDV metabolism sponsored by the AIDS Clinical Trials Group (protocol 161). Plasma and intracellular pharmacokinetics following a 100 mg oral dose of ZDV were determined at weeks 4 and 24 of initial therapy in adult patients. Plasma concentrations and phosphorylated ZDV were determined by radioimmunoassay, and area under the concentration-time curves (AUC) were compared with clinical data collected during the pharmacokinetic study.
Setting: An outpatient setting at the University of Cincinnati AIDS Treatment Center, Cincinnati, Ohio, USA.
Patients: HIV-infected adults with CD4+ lymphocyte counts 200-500 x 10(6) cells/l with no prior history of anti-HIV therapy and no active infections requiring systemic therapy. Of 30 patients enrolled, 21 were evaluable.
Interventions: None.
Main outcome measures: AUC of plasma ZDV and intracellular total phosphorylated ZDV were compared with change from baseline of the following surrogate markers: CD4+ lymphocyte count, %CD4+ lymphocytes, CD4+/CD8+ cell ratio, serum beta 2-microglobulin, serum neopterin, neutrophils, red cell count, and hemoglobin.
Results: No correlations between plasma AUC and markers of therapeutic response were observed. However, significant positive correlations were observed between the AUC of total phosphorylated ZDV and changes in the %CD4+ lymphocytes and CD4+/CD8+ lymphocyte ratio; a negative correlation was observed with change in hemoglobin. Patients who responded to ZDV therapy, as measured by these variables, demonstrated significantly higher intracellular AUC (> 3 pmol x h/10(6) cells) than those who did not (approximately 2 pmol x h/10(6) cells).
Conclusions: The ability of HIV-infected patients to phosphorylate ZDV correlates with changes in markers associated with drug effect and toxicity. Potential individualization of therapy through monitoring of total phosphorylated ZDV in patients therefore warrants further exploration.
Similar articles
-
Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.Pediatr AIDS HIV Infect. 1997 Apr;8(2):120-6. Pediatr AIDS HIV Infect. 1997. PMID: 11361778
-
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.BMJ. 1991 Jan 12;302(6768):73-8. doi: 10.1136/bmj.302.6768.73. BMJ. 1991. PMID: 1671651 Free PMC article.
-
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.Aust N Z J Med. 2000 Feb;30(1):11-20. doi: 10.1111/j.1445-5994.2000.tb01048.x. Aust N Z J Med. 2000. PMID: 10800872 Clinical Trial.
-
Zalcitabine.Ann Pharmacother. 1993 Apr;27(4):480-9. doi: 10.1177/106002809302700416. Ann Pharmacother. 1993. PMID: 8097417 Review.
-
Metabolism of Zidovudine.Gen Pharmacol. 1995 Nov;26(7):1469-75. doi: 10.1016/0306-3623(95)00047-x. Gen Pharmacol. 1995. PMID: 8690233 Review.
Cited by
-
Clinically significant interactions with drugs used in the treatment of tuberculosis.Drug Saf. 2002;25(2):111-33. doi: 10.2165/00002018-200225020-00005. Drug Saf. 2002. PMID: 11888353 Review.
-
Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults.Infection. 1995 Nov-Dec;23(6):344-8. doi: 10.1007/BF01713563. Infection. 1995. PMID: 8655204 Clinical Trial.
-
Pharmacokinetics of Tenofovir Diphosphate, Lamivudine Triphosphate and Emtricitabine Triphosphate in Adolescents With HIV Infection With and Without Tuberculosis Coinfection.Pediatr Infect Dis J. 2025 Apr 10;44(9):876-881. doi: 10.1097/INF.0000000000004831. Pediatr Infect Dis J. 2025. PMID: 40233329
-
Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.Drugs. 1996 Aug;52(2):168-85. doi: 10.2165/00003495-199652020-00002. Drugs. 1996. PMID: 8841736
-
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.Antimicrob Agents Chemother. 2007 Jun;51(6):2105-11. doi: 10.1128/AAC.00831-06. Epub 2007 Apr 16. Antimicrob Agents Chemother. 2007. PMID: 17438052 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials